Merck Submits New Drug Application for Antithrombotic Vorapaxar

Vorapaxar is for the secondary prevention of cardiovascular events in patients who had a history of heart attack

 

July 25, 2013

July 25, 2013 — Merck announced that the New Drug Application (NDA) for its investigational anti-thrombotic medicine, vorapaxar, has been accepted for standard review by the U.S. Food and Drug Administration (FDA).

Merck is seeking FDA approval of vorapaxar for the secondary prevention of cardiovascular events in patients with a history of heart attack and no history of stroke or transient ischemic attack (TIA).

For more information: www.merck.com

The content of this field is kept private and will not be shown publicly.
By submitting this form, you accept the Mollom privacy policy.